



Supplementary Fig. 1







A



B




Supplementary Fig.2




Supplementary Fig. 3

A MICAL1 CC domain (925-961 residues):
FCKAQTIQRRRLNEIE**A**ALRELEAEGVKLELALRRQSS










B MICAL1 CC domain (925-961 residues) A940P, A941P:
FCKAQTIQRRRLNEIE**P**PLRELEAEGVKLELALRRQSS




Supplementary Fig. 4


MICAL2/MICAL1



Supplementary Fig. 5A



Supplementary Fig. 5B






Supplementary Fig. 5C




α -tubulin

Merge




HA-MICAL1




HA-MICAL1-FAD



HA-MICAL2





Supplementary Fig. 5D





Supplementary Fig. 6

Mock



MICAL3-SiRNA



Supplementary Fig. 7

